Search

The Lighthouse 2 study is a phase 3 clinical trial in which we will investigate the efficacy of the drug Triumeq.

The MAGNET lithium trial studies the efficacy of lithium carbonate in ALS patients positive for the homozygous UNC13A mutation.

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with ALS.

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS.

This phase 1 clinical trial is evaluating the safety, tolerability & pharmacokinetics of the drug ‘BIIB105’ in people living with ALS.

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS.

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS.

This study is designed to test the efficacy and safety of intravenous Ravulizumab in patients with ALS.

Neurologist & leader Project MinE

The Karolinska ALS Clinical Research Group was created by Caroline Ingre in 2015, with the goal to create a dedicated ALS research group. Our group is composed of clinicians (doctors, nurses and assistant nurses), post-docs, PhD students and interns.

ENCALS 2025 will take place in Turin, Italy.

The International Symposium is the biggest annual conference dedicated to ALS and MND research.